Document is current
Any future updates will be listed below
-
Authors
Zhou, Nicolas https://orcid.org/0000-0002-8340-9113
Leung, Cheuk H
William, William N Jr
Weissferdt, Annikka
Pataer, Apar
Godoy, Myrna C B
Carter, Brett W
Fossella, Frank V
Tsao, Anne S
Blumenschein, George R
Le, Xiuning
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Skoulidis, Ferdinandos
Kurie, Jonathan M
Altan, Mehmet https://orcid.org/0000-0001-9229-156X
Lu, Charles
Glisson, Bonnie S
Byers, Lauren A
Elamin, Yasir Y
Mehran, Reza J
Rice, David C
Walsh, Garrett L
Hofstetter, Wayne L
Roth, Jack A
Tran, Hai T
Wu, Jia
Solis Soto, Luisa M
Kadara, Humam
Swisher, Stephen G
Vaporciyan, Ara A
Gibbons, Don L
Lin, Heather Y
Lee, J Jack https://orcid.org/0000-0001-5469-9214
Heymach, John V
Negrao, Marcelo V https://orcid.org/0000-0001-8938-6699
Sepesi, Boris
Cascone, Tina https://orcid.org/0000-0003-3008-5407
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03158129 at ClinicalTrials.govnct03433469 at ClinicalTrials.govDocuments that mention this clinical trial
1242 Integrative machine learning for identifying treatment-specific impacts and biomarkers applied to multi-platform data from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies
https://doi.org/10.1136/jitc-2024-sitc2024.1242
277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy
https://doi.org/10.1136/jitc-2020-sitc2020.0277
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
590 Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0590
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009677
962 Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.962
nct04351555 at ClinicalTrials.govDocuments that mention this clinical trial
Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection
https://doi.org/10.1136/bmjonc-2025-001002
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
https://doi.org/10.1200/jco.24.00071
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009677
Phase II trial of neoadjuvant osimertinib for surgically resectable <i>EGFR</i>-mutated non-small cell lung cancer.
https://doi.org/10.1200/jco.2023.41.16_suppl.8508
nct04302025 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
https://doi.org/10.1200/jco-25-00883
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009677
Documents that mention this clinical trial
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009677
-
Funding
Funding for this research was provided by:
Nahyan Foundation
Bob Mayberry Foundation
MD Anderson Cancer Center Physician Scientist Program
Rexanna’s Foundation for Fighting Lung Cancer
NIH/NCI (P30 CA016672)
NIH/NCI (R01CA262425)
NIH/NCI (U01CA264583)
Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Scholar Award)
Andrew Sabin Family Foundation
Conquer Cancer Foundation of the American Society of Clinical Oncology
Lung Specialized Program of Research Excellence SPORE (5P50CA070907)
MD Anderson Cancer Center Lung Cancer Moon Shot Program
Bristol Myers Squibb
- License Information
